Trial
NCT02150967
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
QED Therapeutics, a BridgeBio company
Collaborators
Helsinn Healthcare SA
Condition
Advanced Cholangiocarcinoma
Intervention
BGJ398 (infigratinib)
Why stopped
The study was terminated early due to limited efficacy in Cohorts 2 and 3 (exploratory endpoints). Termination was not due to concerns about safety and had no impact on the primary efficacy analysis (ie, results reported for Cohort 1).
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-07-03